BT Investment Management Ltd acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 69,967 shares of the biotechnology company’s stock, valued at approximately $9,077,000. BT Investment Management Ltd owned approximately 0.16% of United Therapeutics Corporation at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. HPM Partners LLC raised its holdings in shares of United Therapeutics Corporation by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 15 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in shares of United Therapeutics Corporation by 0.3% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock valued at $1,712,000 after buying an additional 40 shares in the last quarter. Fisher Asset Management LLC raised its holdings in shares of United Therapeutics Corporation by 1.4% during the 2nd quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock valued at $411,000 after buying an additional 45 shares in the last quarter. Argent Capital Management LLC raised its holdings in shares of United Therapeutics Corporation by 2.4% during the 1st quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 60 shares in the last quarter. Finally, Synovus Financial Corp raised its holdings in shares of United Therapeutics Corporation by 1.2% during the 2nd quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock valued at $731,000 after buying an additional 69 shares in the last quarter.

In other news, Director Christopher Causey sold 590 shares of the stock in a transaction that occurred on Thursday, July 6th. The stock was sold at an average price of $132.61, for a total value of $78,239.90. Following the sale, the director now directly owns 3,875 shares in the company, valued at $513,863.75. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Raymond Dwek sold 3,490 shares of the stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $131.71, for a total value of $459,667.90. The disclosure for this sale can be found here. Insiders sold a total of 25,198 shares of company stock valued at $3,281,816 over the last ninety days. Corporate insiders own 7.80% of the company’s stock.

United Therapeutics Corporation (NASDAQ:UTHR) opened at 120.79 on Friday. The firm has a 50-day moving average price of $128.92 and a 200-day moving average price of $129.77. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89. The stock has a market capitalization of $5.25 billion, a PE ratio of 14.01 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million during the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. United Therapeutics Corporation’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $4.42 earnings per share. Equities research analysts predict that United Therapeutics Corporation will post $10.09 EPS for the current fiscal year.

A number of brokerages recently weighed in on UTHR. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. Jefferies Group LLC reissued a “sell” rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, June 8th. ValuEngine cut United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Friday, September 8th. BidaskClub cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Finally, UBS AG reissued a “sell” rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Six research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the stock. United Therapeutics Corporation presently has an average rating of “Hold” and a consensus price target of $134.50.

TRADEMARK VIOLATION WARNING: This article was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/17/bt-investment-management-ltd-acquires-shares-of-69967-united-therapeutics-corporation-uthr.html.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.